NASDAQ$ADVM
Adverum Biotechnologies Inc · Q4 2022 earnings
Q4 2022 earnings · · Investor relations
Briefing
Adverum Biotechnologies reported financial results for the fourth quarter and full year ended December 31, 2022 and provided an update on its ongoing Phase 2 LUNA trial.
Adverum Biotechnologies reported a net loss of $32.7 million for the fourth quarter of 2022, with cash, cash equivalents, and short-term investments totaling $185.6 million as of December 31, 2022. The company expects its cash runway to fund operations into 2025 and anticipates full enrollment of the LUNA trial in the second half of 2023, with preliminary efficacy and safety data expected in the fourth quarter of 2023.
- Phase 2 LUNA trial continues to enroll, with enthusiasm from investigators and progress in participant screening.
- Full enrollment of the LUNA trial is anticipated in the second half of 2023.
- LUNA 14-week data including initial aflibercept levels anticipated in the third quarter 2023.
- LUNA preliminary efficacy and safety data anticipated in the fourth quarter of 2023.
Headline financials
Revenue & EPS history
Adverum · Revenue · Quarterly
$0
Forward guidance
Adverum anticipates full enrollment of the Phase 2 LUNA trial in the second half of 2023 and expects cash, cash equivalents and short-term investments to fund operations into 2025.
Tailwinds
- Full enrollment of the LUNA trial anticipated in the second half of 2023
- LUNA 14-week data including aflibercept levels anticipated in the third quarter 2023
- LUNA preliminary efficacy and safety data anticipated in the fourth quarter of 2023
- Cash runway into 2025
- Engaging with European health authorities in anticipation of enrolling LUNA subjects in Europe, in addition to the U.S. clinical trial sites
Headwinds
- Uncertainties regarding the timing of commencement and completion of clinical trials.
- Regulatory uncertainties.
- Enrollment uncertainties.
- The results of early clinical trials not always being predictive of future clinical trials and results.
- The potential for future complications or side effects in connection with use of Ixo-vec.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 15 quarterly earnings reports · overlaid with Q4 2022
+0.0%
Avg return
Earnings day
-0.8%
Avg return
5 days after
-2.5%
Avg return
30 days after
45%
17 / 38 earnings
Positive
+12.5%
Q3 2022
Best reaction
-15.5%
Q2 2020
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2025 | — | — | — | |
| Q3 2025 | -0.9% | -1.2% | — | |
| Q2 2025 | +10.8% | +27.9% | +41.4% | |
| Q1 2025 | -1.0% | +21.0% | +19.5% | |
| Q4 2024 | -5.8% | -15.4% | -41.0% | |
| Q3 2024 | +4.2% | +8.4% | -18.5% | |
| Q2 2024 | +3.0% | +4.7% | +7.3% | |
| Q1 2024 | -5.2% | -9.3% | -25.1% | |
| Q4 2023 | -2.9% | -5.3% | -33.1% | |
| Q3 2023 | +1.8% | -3.4% | +0.0% | |
| Q2 2023 | +2.2% | -3.8% | -7.1% | |
| Q1 2023 | -4.6% | -4.1% | +89.3% | |
| Q4 2022 | -4.5% | -6.7% | +3.6% | |
| Q3 2022 | +12.5% | +3.2% | -9.6% | |
| Q2 2022 | -4.5% | -8.6% | -25.0% | |
| Q1 2022 | -14.1% | -13.5% | +2.7% | |
| Q4 2021 | -2.9% | -5.8% | -20.3% | |
| Q3 2021 | -5.6% | -1.3% | -24.9% | |
| Q2 2021 | +6.9% | — | — | |
| Q1 2021 | +3.3% | — | — | |
| Q4 2020 | -5.3% | — | — | |
| Q3 2020 | -7.8% | — | — | |
| Q2 2020 | -15.5% | — | — | |
| Q1 2020 | -1.9% | — | — | |
| Q4 2019 | +11.6% | — | — | |
| Q3 2019 | +8.9% | — | — | |
| Q2 2019 | -1.3% | — | — | |
| Q1 2019 | -3.7% | — | — | |
| Q4 2018 | +2.8% | — | — | |
| Q3 2018 | +1.9% | — | — | |
| Q2 2018 | +10.9% | — | — | |
| Q1 2018 | +3.6% | — | — | |
| Q4 2017 | -4.1% | — | — | |
| Q3 2017 | -6.3% | — | — | |
| Q2 2017 | -2.0% | — | — | |
| Q1 2017 | -1.8% | — | — | |
| Q3 2016 | +11.9% | — | — | |
| Q2 2016 | +2.3% | — | — | |
| Q3 2014 | +4.5% | — | — | |
| Q2 2014 | — | — | — | |
| Q1 2014 | — | — | — | |
| Q4 2014 | — | — | — | |
| Q3 2013 | — | — | — | |
| Q2 2013 | — | — | — | |
| Q1 2013 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro